MedTrace Logo

PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)

NCT06074692 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2023-10-31

No results posted yet for this study

Summary

The aim of this study is to evaluate the efficacy and safety of PARP Inhibition and programmed cell death protein-1 (PD-1) blockade immunotherapy with concurrent stereotactic body radiotherapy (SBRT) for metastatic or advanced bone and soft tissue sarcoma.

Conditions

  • Sarcoma
  • Sarcoma,Soft Tissue
  • Sarcoma of Bone

Interventions

COMBINATION_PRODUCT

Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)

Patients receive Camrelizumab (PD-1 inhibitor) and fluzoparib (PARP inhibitor) with concurrent stereotactic body radiotherapy (SBRT)

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Weibin Zhang, PhD, MD · Ruijin Hospital

  • Yuhui Shen, PhD, MD · Ruijin Hospital

  • Qiyuan Bao, PhD, MD · Ruijin Hospital

  • Junxiang Wen, PhD, MD · Ruijin Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2026-08-30
Completion
2026-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06074692 on ClinicalTrials.gov